tiprankstipranks
Trending News
More News >
Ypsomed Holding AG (CH:YPSN)
:YPSN

Ypsomed Holding AG (YPSN) AI Stock Analysis

Compare
0 Followers

Top Page

CH

Ypsomed Holding AG

(LSE:YPSN)

Rating:60Neutral
Price Target:―
Ypsomed Holding AG's strength lies in its solid financial performance with strong revenue growth and profitability. However, the stock faces challenges with an overvaluation and moderate technical indicators. The lack of recent earnings guidance or corporate events leaves the focus on improving cash flow management to drive future growth.

Ypsomed Holding AG (YPSN) vs. iShares MSCI Switzerland ETF (EWL)

Ypsomed Holding AG Business Overview & Revenue Model

Company DescriptionYpsomed Holding AG (YPSN) is a Swiss-based company engaged in the development and manufacturing of injection and infusion systems for self-medication, with a focus on diabetes management. It operates in the medical technology sector, providing innovative solutions for insulin delivery and other therapeutic areas. The company offers a range of products, including insulin pumps, pen injectors, and related accessories, catering to both healthcare professionals and patients.
How the Company Makes MoneyYpsomed Holding AG generates revenue primarily through the sale of its medical devices and solutions for self-medication. Key revenue streams include the direct sale of insulin pumps, pen injectors, and infusion sets, as well as the provision of related services. The company also licenses its technology to pharmaceutical companies, which contributes to its earnings. Significant partnerships with global pharmaceutical companies enhance its market reach and product distribution, further driving revenue growth. Ypsomed's focus on innovation and expanding its product portfolio supports its financial performance in the competitive medical technology industry.

Ypsomed Holding AG Financial Statement Overview

Summary
Ypsomed Holding AG exhibits strong financial performance with robust revenue growth and profitability. The balance sheet reflects stability with low leverage, though improvement is needed in cash flow generation, particularly in free cash flow management.
Income Statement
85
Very Positive
Ypsomed Holding AG has shown a strong performance in its income statement with a notable revenue growth rate of 10.24% from 2023 to 2024. The gross profit margin stands at a healthy 34.47%, and the net profit margin is 14.29%, indicating efficient cost management and profitability. EBIT and EBITDA margins are also robust at 15.72% and 29.5%, respectively. The consistent revenue growth and profitability reflect a positive trajectory for the company.
Balance Sheet
75
Positive
The balance sheet of Ypsomed Holding AG shows a solid equity base with an equity ratio of 56.09%, highlighting financial stability. The debt-to-equity ratio is 0.41, which is relatively low and indicates conservative leverage. However, the return on equity (ROE) of 12.69% suggests moderate efficiency in using equity capital to generate profits. Overall, the balance sheet is stable but has room for improvement in maximizing returns on equity.
Cash Flow
70
Positive
Ypsomed Holding AG's cash flow statement reveals a mixed picture. The operating cash flow to net income ratio is 2.08, demonstrating strong cash generation relative to its net income. However, the free cash flow growth rate remains negative, and the free cash flow to net income ratio is -0.41, indicating a need to improve capital expenditure management to enhance free cash flow.
Breakdown
TTMMar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Income StatementTotal Revenue
617.07M548.46M497.46M464.84M403.66M394.26M
Gross Profit
218.66M189.05M140.59M113.82M94.83M90.97M
EBIT
86.84M86.22M37.30M24.40M769.00K1.82M
EBITDA
145.13M161.78M137.51M92.48M63.86M61.63M
Net Income Common Stockholders
74.39M78.37M51.27M23.11M5.81M11.73M
Balance SheetCash, Cash Equivalents and Short-Term Investments
38.88M74.02M25.22M17.04M22.41M22.33M
Total Assets
421.80M1.10B861.88M756.91M717.68M678.24M
Total Debt
10.00M256.00M157.00M267.00M215.00M193.00M
Net Debt
-28.88M181.98M132.52M251.14M196.85M180.83M
Total Liabilities
120.00M483.66M291.57M356.63M313.54M292.89M
Stockholders Equity
301.80M617.74M562.33M392.54M395.38M377.66M
Cash FlowFree Cash Flow
-8.11M-32.09M-39.64M-41.72M-40.75M-69.64M
Operating Cash Flow
156.69M163.22M129.53M85.71M85.83M49.09M
Investing Cash Flow
-234.23M-195.07M-122.02M-125.70M-106.91M-115.83M
Financing Cash Flow
94.35M81.07M1.26M38.12M26.67M68.66M

Ypsomed Holding AG Technical Analysis

Technical Analysis Sentiment
Positive
Last Price407.50
Price Trends
50DMA
353.54
Positive
100DMA
353.51
Positive
200DMA
370.44
Positive
Market Momentum
MACD
17.60
Negative
RSI
75.87
Negative
STOCH
87.97
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:YPSN, the sentiment is Positive. The current price of 407.5 is above the 20-day moving average (MA) of 380.70, above the 50-day MA of 353.54, and above the 200-day MA of 370.44, indicating a bullish trend. The MACD of 17.60 indicates Negative momentum. The RSI at 75.87 is Negative, neither overbought nor oversold. The STOCH value of 87.97 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:YPSN.

Ypsomed Holding AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
$4.28B25.5818.36%0.40%1.82%39.11%
66
Neutral
CHF2.70B38.7220.81%0.48%13.35%50.65%
61
Neutral
$2.10B30.914.84%1.74%-13.04%-48.74%
60
Neutral
CHF5.62B64.3413.49%0.48%21.33%2.72%
54
Neutral
$5.31B3.29-45.39%2.79%16.77%-0.07%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CH:YPSN
Ypsomed Holding AG
414.50
22.95
5.86%
CH:MOVE
Medacta Group SA
135.00
8.63
6.83%
CH:SFZN
Siegfried Holding AG
97.10
6.29
6.93%
CH:TECN
Tecan Group AG
163.80
-144.63
-46.89%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.